Disitamab Vedotin

Antibody–drug conjugate

Also known as PF-08046051

Approvedregulatory verdict

Evidence outlook

Approved: With toripalimab, first-line HER2-expressing (IHC 1+/2+/3+) locally advanced or... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the USGastric Cancer · Phase 3 · investigational in the USHER2-Positive Breast Cancer · Phase 2/3 · investigational in the USUrothelial Carcinoma · Phase 3 · investigational in the US

Also approved (5)
CN
  • With toripalimab, first-line HER2-expressing (IHC 1+/2+/3+) locally advanced or metastatic urothelial cancerwww1.hkexnews.hk
  • HER2-low (IHC 1+ or IHC 2+/ISH-) unresectable or metastatic breast cancer with liver metastases after at least one systemic therapy. Label does not mention hormone receptor status, so not mapped to the HR+/HER2- market.www1.hkexnews.hk
  • HER2-positive advanced breast cancer with liver metastases after trastuzumab (or biosimilar) and a taxanewww1.hkexnews.hk
  • Conditional approval: HER2-expressing urothelial cancer, second-line and laterwww1.hkexnews.hk
  • Conditional approval: HER2-expressing third-line and later gastric cancerwww1.hkexnews.hk
Product first approved 2021

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Gastric Cancer
NCT04714190 · RemeGen Co., Ltd.
2021-03-24 – 2025-06-30 · Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05904964 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2030-03-01 · HR Positive/HER2 Low Expression Metastatic Breast Cancer
What this study did
Urothelial Carcinoma
NCT07498907 · Peking University First Hospital
2026-05-01 – 2034-03-01 · Upper Tract Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06278870 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-09-06 – 2031-06-30 · HER2-positive Metastatic Breast Cancer, First-line Treatment
What this study did
NCT07693959 · Zhiquan Hu
2026-07-01 – 2029-07-01 · MIBC
What this study did
Phase 2/3 (5)
Gastric Cancer
NCT06221748 · RemeGen Co., Ltd.
2024-02-22 – 2027-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
HER2-Positive Breast Cancer
NCT07366840 · Fudan University
2026-01-16 – 2029-01-16 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT03500380 · RemeGen Co., Ltd.
2018-04-24 – 2024-12-31 · Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
What this study did
Other / comorbidity
NCT07608224 · West China Hospital
2026-06-20 – 2030-12-31 · Urinary Bladder Neoplasms
What this study did
Phase 2 (96)
Gastric Cancer
NCT07474324 · The First Affiliated Hospital with Nanjing Medical University
2026-03-15 – 2030-12-31 · GC/GEJC
What this study did
NCT06157892 · Seagen, a wholly owned subsidiary of Pfizer
2024-05-20 – 2029-07-28 · Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
What this study did
NCT07490990 · West China Hospital
2026-06 – 2028-12 · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07194005 · Fudan University
2025-09-04 – 2028-09-30 · Gastric Cancer
What this study did
NCT06560528 · Tianjin Medical University Cancer Institute and Hospital
2024-09-01 – 2028-09-01 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06487429 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-05-08 – 2028-05-31 · Gastric Cancer
What this study did
NCT06385873 · The First Affiliated Hospital with Nanjing Medical University
2024-05-01 – 2028-05-01 · Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07507526 · Sun Yat-sen University
2026-04 – 2028-04-30 · Gastric Adenocarcinoma
What this study did
NCT06155383 · RemeGen Co., Ltd.
2023-11-27 – 2027-12-31 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06730373 · Qilu Hospital of Shandong University
2024-10-17 – 2027-12-31 · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
What this study did
NCT06492317 · The First Affiliated Hospital of Zhengzhou University
2024-07-06 – 2027-07-06 · HER2-positive Gastric Cancer
What this study did
NCT06227325 · Henan Cancer Hospital
2024-02-01 – 2025-12-31 · Gastric Cancer
What this study did
NCT05586061 · Qilu Hospital of Shandong University
2023-02-10 – 2025-12-31 · HER2-positive Gastric Cancer
What this study did
NCT05928897 · Xiangya Hospital of Central South University
2023-07-01 – 2025-07-01 · Gastric Cancer
What this study did
NCT05241899 · The First Affiliated Hospital of Zhengzhou University
2022-05-07 – 2025-05-07 · Gastric Cancer
What this study did
NCT05720533 · Tianjin Medical University Cancer Institute and Hospital
2023-03-01 – 2025-03-01 · Gastric Cancer
What this study did
NCT05627414 · Tianjin Medical University Cancer Institute and Hospital
2023-01-01 – 2025-01-01 · Gastric Cancer
What this study did
NCT05113459 · Guoxin Li
2021-12-18 – 2024-06-18 · Gastric Cancer
What this study did
NCT05313906 · Henan Cancer Hospital
2022-05-07 – 2024-04-30 · Advanced Gastric Carcinoma, HER2-positive Gastric Cancer
What this study did
NCT03556345 · RemeGen Co., Ltd.
2018-07-10 – 2020-08-31 · Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
What this study did
HER2-Positive Breast Cancer
NCT06178159 · RemeGen Co., Ltd.
2023-11-28 – 2026-12 · Breast Cancer
What this study did
NCT05134519 · Xijing Hospital
2021-11-26 – 2025-09-30 · Breast Cancer, HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06642545 · RemeGen Co., Ltd.
2025-02-10 – 2027-10-01 · Breast Cancer
What this study did
NCT07446452 · The First Affiliated Hospital with Nanjing Medical University
2024-01-01 – 2027-01-01 · HER2-low Breast Cancer
What this study did
NCT06000033 · Qilu Hospital of Shandong University
2023-08-10 – 2025-12-31 · Breast Cancer
What this study did
NCT05331326 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-04 – 2024-08 · Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06734182 · Guangdong Provincial People's Hospital
2024-06-22 – 2028-06-22 · Non-small Cell Lung Cancer
What this study did
NCT06185400 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-02-01 – 2026-12-01 · Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
What this study did
NCT05847764 · Sun Yat-sen University
2023-05 – 2025-05 · Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
What this study did
Urothelial Carcinoma
NCT07720921 · Peking University First Hospital
2026-11-01 – 2029-08-01 · Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
What this study did
NCT04879329 · Seagen, a wholly owned subsidiary of Pfizer
2022-05-03 – 2029-04-14 · Urothelial Carcinoma
What this study did
NCT07717242 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-07-01 – 2029-01-31 · Bladder Urothelial Carcinoma, Bladder Cancer
What this study did
NCT07584733 · RenJi Hospital
2026-05-31 – 2028-12-31 · Upper Tract Urothelial Carcinoma
What this study did
NCT05917158 · Jinling Hospital, China
2022-11-23 – 2028-12 · Carcinoma, Upper Tract Urothelial Carcinoma, UTUC
What this study did
NCT07279597 · Tongji Hospital
2025-12-10 – 2028-08-01 · Muscle-invasive Bladder Urothelial Carcinoma
What this study did
NCT07591805 · RenJi Hospital
2026-05-16 – 2028-01-31 · Upper Urinary Tract Urothelial Carcinoma
What this study did
NCT06904573 · Sun Yat-sen University
2025-01-01 – 2028-01-01 · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
What this study did
NCT05912816 · RenJi Hospital
2023-06-10 – 2026-12-30 · Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
What this study did
NCT05912205 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-07-01 – 2026-07-01 · Urothelial Carcinoma
What this study did
NCT06178601 · Shanxi Province Cancer Hospital
2023-08-03 – 2026-04-01 · Urothelial Carcinoma
What this study did
NCT05495724 · Tianjin Medical University Second Hospital
2021-07-23 – 2025-07 · Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
What this study did
NCT04073602 · RemeGen Co., Ltd.
2019-08-19 – 2023-01-31 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT07474064 · chenxu
2026-03-26 – 2035-03-31 · Muscle Invasive Bladder Cancer (MIBC)
What this study did
Phase 1/2 (16)
Gastric Cancer
NCT06572319 · Zhejiang Cancer Hospital
2024-09-01 – 2026-12-31 · HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05982834 · Fudan University
2023-05-09 – 2025-12 · HER2-positive Gastric Cancer, Immunotherapy
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06966453 · Pfizer
2025-06-30 – 2030-01-27 · Breast Cancer, Breast Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT05745740 · RemeGen Co., Ltd.
2027-12-01 – 2028-12-01 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT04264936 · Peking University Cancer Hospital & Institute
2020-02-15 – 2021-12-31 · Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06417554 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-05-27 – 2031-12-31 · Advanced Solid Tumors
What this study did
NCT06378242 · RemeGen Co., Ltd.
2024-06-14 – 2029-12-31 · High-risk Non-muscle Invasive Bladder Cancer
What this study did
NCT06957561 · Sun Yat-sen University
2025-04-30 – 2029-05-01 · Bladder Cancer, Muscle-invasive Bladder Cancer
What this study did
NCT06650332 · Zhejiang Cancer Hospital
2024-07-10 – 2027-12-30 · Metastatic HER2 Positive Gastroesophageal Junction Cancer
What this study did
NCT06663007 · Tianjin Medical University Second Hospital
2024-09-24 – 2027-08-31 · Prostate Cancer, CDK12 Gene Mutation
What this study did
NCT05403242 · Chinese PLA General Hospital
2022-09-20 – 2026-09 · Advanced Gastroesophageal Adenocarcinoma
What this study did
NCT05898373 · Peking Union Medical College
2023-06-07 – 2026-06-06 · Salivary Gland Cancer
What this study did
NCT06016062 · RemeGen Co., Ltd.
2023-09-14 – 2025-12-31 · Solid Tumor
What this study did
NCT06055153 · Changhai Hospital
2023-09-30 – 2025-04-30 · Esophageal Squamous Carcinoma, HER-2 Protein Overexpression
What this study did
Phase 1 (9)
Gastric Cancer
NCT06078982 · Shanghai East Hospital
2023-06-06 – 2025-08 · Gastric Cancer, HER2-low-expressing Gastric Cancer
What this study did
Other / comorbidity
NCT07853053 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2027-01-01 – 2029-12-31 · Bladder Cancer
What this study did
NCT05940896 · RemeGen Co., Ltd.
2023-06-29 – 2027-02-28 · Solid Tumor
What this study did
NCT06660511 · Second Xiangya Hospital of Central South University
2024-10-15 – 2026-12-15 · Ovarian Cancer Recurrent
What this study did
NCT04280341 · Peking University
2020-06-03 – 2024-12 · HER2-Positive Solid Tumors
What this study did
NCT02881138 · RemeGen Co., Ltd.
2016-03-01 – 2020-07-15 · Solid Tumors
What this study did
NCT02881190 · RemeGen Co., Ltd.
2015-12-14 – 2019-11-08 · Solid Tumors
What this study did
Phase 4 (4)
Urothelial Carcinoma
NCT05488353 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2022-09-01 – 2026-04-30 · Bladder Cancer
What this study did
NCT05723991 · Chunguang yang (101937)
2022-09-28 – 2025-09-28 · Radical Cystectomy, Urothelial Carcinoma
What this study did
Other / comorbidity
NCT05861635 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-02-01 – 2026-02-01 · Breast Cancer, Neoadjuvant Therapy
What this study did
NCT05661357 · Zhongnan Hospital
2023-01-01 – 2025-12-31 · HER2, Colorectal Cancer
What this study did
Early phase / not applicable (4)
HER2-Positive Breast Cancer
NCT06015113 · Xi'an International Medical Center Hospital
2023-09 – 2027-04 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05831878 · RenJi Hospital
2023-05-04 – 2027-12 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT06558682 · Qilu Hospital of Shandong University
2024-10-20 – 2026-10-01 · Uterine Cervical Neoplasms
What this study did
NCT05540483 · The First Affiliated Hospital with Nanjing Medical University
2022-08-01 – 2025-08-01 · Biliary Carcinoma
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Urothelial Carcinoma
NCT07756008 · Tianjin Medical University Second Hospital
2026-08-01 – 2031-06-20 · Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT06105008 · RemeGen Co., Ltd.
2024-12-20 – 2026-04-10 · Breast Neoplasms
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Disitamab Vedotin: this drugPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(59 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Disitamab Vedotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
December 2026 (8)
Phase 2/3Gastric CancerRecruiting
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05831878 · CT.gov ↗
What to watch
Phase 1Ovarian Cancer RecurrentRecruiting
Est. primary completion 2026-12-01 · NCT06660511 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-06 · NCT07446452 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-11 · NCT04879329 · CT.gov ↗
What to watch
Phase 2mCRPCRecruiting
Est. primary completion 2026-12-30 · NCT07093866 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06730373 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05302284 · CT.gov ↗
What to watch
2027 (27)
January 2027 (5)
Phase 2Paget Disease, Extramammary, Scrotum DiseaseRecruiting
Est. primary completion 2027-01 · NCT06791070 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, HER2Recruiting
Est. primary completion 2027-01-04 · NCT07285941 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-29 · NCT05911295 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-01-31 · NCT07591805 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Recurrent Cervical CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07172217 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Non-Muscle-Invasive Bladder Cancer (NMIBC)Recruiting
Est. primary completion 2027-04 · NCT07646145 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-05-17 · NCT06420973 · CT.gov ↗
What to watch
Phase 1/2Prostate Cancer, CDK12 Gene MutationRecruiting
Est. primary completion 2027-05-31 · NCT06663007 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-22 · NCT06734182 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2027-06-30 · NCT06155396 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07720921 · CT.gov ↗
What to watch
Phase 2UrologyNot yet recruiting
Est. primary completion 2027-08-30 · NCT07151560 · CT.gov ↗
What to watch
September 2027 (2)
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07783815 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-09-01 · NCT06560528 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Sebaceous Gland CarcinomaNot yet recruiting
Est. primary completion 2027-10-01 · NCT07740993 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-10-25 · NCT06966453 · CT.gov ↗
What to watch
December 2027 (8)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-12 · NCT05917158 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-10 · NCT07279597 · CT.gov ↗
What to watch
Phase 2Extramammary Paget Disease, Scrotum DiseaseRecruiting
Est. primary completion 2027-12-30 · NCT07117851 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07201675 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer Metastatic, Ovarian Cancer Metastatic RecurrentRecruiting
Est. primary completion 2027-12-30 · NCT07311577 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07584733 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT04400695 · CT.gov ↗
What to watch
2028 (14)
January 2028 (1)
Phase 2/3HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-01-16 · NCT07366840 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates, Immunotherapy, Chemotherapy, Systemic TherapyNot yet recruiting
Est. primary completion 2028-03-01 · NCT07879469 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-01 · NCT05904964 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07507526 · CT.gov ↗
What to watch
May 2028 (3)
Phase 3Gastric CarcinomaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
Phase 2HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBTNot yet recruiting
Est. primary completion 2028-05-31 · NCT07100184 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT06210490 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07490990 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07717242 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3MIBCRecruiting
Est. primary completion 2028-07-01 · NCT07693959 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Ovary CancerRecruiting
Est. primary completion 2028-08-01 · NCT06540729 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-09-30 · NCT07194005 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-12-31 · NCT07474324 · CT.gov ↗
What to watch
2029 (6)
March 2029 (1)
Phase 1/2High-risk Non-muscle Invasive Bladder CancerRecruiting
Est. primary completion 2029-03-15 · NCT06378242 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2029-04-10 · NCT07509424 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2029-05-01 · NCT07498907 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Gastric CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT07315750 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07853053 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 2/3Urinary Bladder NeoplasmsNot yet recruiting
Est. primary completion 2030-06-30 · NCT07608224 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2031-03-31 · NCT07474064 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting
Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗
What to watch
December 2031 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2031-12-31 · NCT06417554 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 May 2025Topline resultPhase 3 RC48-C016 meets PFS and OS primary endpoints
October 2024Filing acceptedChina BLA accepted for DV in HER2-positive breast cancer with liver metastasis
CN, NMPA · Source ↗
October 2024Priority reviewPriority review granted in China for DV in breast cancer with liver metastasis
CN, NMPA · Source ↗